Mounjaro (tirzepatide) is FDA-approved and considered safe for most adults with type 2 diabetes when used as directed, though it carries specific risks and side effects you should know about. Approved in May 2022, it went through extensive clinical trials involving thousands of participants. Serious adverse events were rare, occurring in less than 1% of users for the most concerning complications, but the drug does cause frequent gastrointestinal side effects and has a boxed warning related to thyroid tumors in animal studies.
Common Side Effects
The most frequent side effects are digestive. Nausea, diarrhea, vomiting, and constipation are the complaints you’re most likely to experience, especially during the first few weeks and after each dose increase. Mounjaro works partly by slowing how fast your stomach empties after a meal, which is why gut-related symptoms are so common.
The good news is that these effects tend to fade over time. The delay in stomach emptying is strongest after your very first dose and gradually lessens as your body adjusts. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help manage symptoms during those early weeks. In clinical trials, between 4% and 7% of participants on Mounjaro stopped the medication because of side effects, compared to about 2.6% on placebo. That means the vast majority of people tolerated it well enough to continue.
The Thyroid Warning
Mounjaro carries the most serious type of FDA warning, a boxed warning, about the risk of thyroid C-cell tumors. In rat studies, tirzepatide caused thyroid tumors at doses relevant to humans, and the risk increased with higher doses and longer treatment. Whether this translates to humans is unknown, and no confirmed link to thyroid cancer has been established in people.
Still, the FDA draws a hard line here. Mounjaro is completely off-limits if you have a personal or family history of medullary thyroid carcinoma, or if you have a rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). While taking Mounjaro, watch for a lump or mass in your neck, trouble swallowing, difficulty breathing, or persistent hoarseness, as these could be signs of thyroid tumors.
Serious but Rare Complications
Acute pancreatitis (sudden, severe inflammation of the pancreas) occurred in less than 1% of clinical trial participants taking Mounjaro. Gallstones were similarly rare, also affecting less than 1% regardless of dose. These are low numbers, but both conditions can be serious. Sudden, severe abdominal pain that doesn’t go away warrants immediate medical attention.
In November 2024, the FDA updated Mounjaro’s label to include a new warning about severe gastrointestinal reactions. In pooled clinical trials, severe GI events occurred in about 0.4% to 1.3% of Mounjaro users depending on dose, compared to 0.9% on placebo. The drug’s postmarketing data also now lists ileus (a type of intestinal blockage) as a reported event. Mounjaro is not recommended for people who already have severe gastrointestinal conditions, including severe gastroparesis (stomach paralysis).
Risk of Low Blood Sugar
On its own, Mounjaro has a low risk of causing dangerously low blood sugar. In clinical trials, it actually performed better than long-acting insulins on this front, with significantly fewer hypoglycemia episodes. At appropriate doses, the risk is comparable to other drugs in the GLP-1 class.
The picture changes if you’re also taking insulin or certain other diabetes medications. Combination therapy increases the chance of low blood sugar, and your provider may need to adjust the doses of your other medications when starting Mounjaro. At the highest dose (15 mg), tirzepatide was associated with somewhat higher hypoglycemia rates than other GLP-1 drugs alone, so the risk at higher doses shouldn’t be completely dismissed.
Effects on Other Medications
Because Mounjaro slows stomach emptying, it can change how quickly your body absorbs other oral medications. This matters most for drugs where timing and absorption are critical.
Oral birth control is the clearest example. Australia’s drug safety authority advises switching to a non-oral contraceptive method (such as an IUD, implant, or patch) or adding a barrier method like condoms for four weeks after starting Mounjaro and for four weeks after each dose increase. The concern is that slower absorption could reduce the pill’s effectiveness during those adjustment windows.
This same principle applies to any medication you take by mouth that requires precise absorption. If you take other time-sensitive medications, your provider may need to monitor their effectiveness or adjust timing.
Anesthesia and Surgery
If you have a surgery or procedure requiring general anesthesia or deep sedation planned, this is worth knowing: rare postmarketing reports describe pulmonary aspiration (food or liquid entering the lungs) in patients on GLP-1 drugs. Because Mounjaro slows digestion, your stomach may still contain food even after following standard fasting instructions before surgery. Make sure any anesthesiologist or surgeon knows you’re taking Mounjaro well ahead of your procedure date.
Pregnancy and Planning to Conceive
Mounjaro has not been studied in pregnant women and should be stopped before pregnancy. Clinical guidelines suggest discontinuing the drug at least two months before trying to conceive, giving your body time to fully clear it. If you discover you’re pregnant while on Mounjaro, stop taking it right away. The rapid weight loss that Mounjaro can cause also has its own implications for fertility and pregnancy nutrition, so planning ahead matters.
Kidney and Liver Considerations
Mounjaro has been specifically studied in people with mild, moderate, and severe liver impairment. The drug has also been evaluated alongside various levels of kidney function, though people with significantly impaired kidneys were excluded from some trials. Severe nausea, vomiting, or diarrhea from Mounjaro can cause dehydration, which may worsen existing kidney problems. Staying well-hydrated is especially important if you have any degree of kidney disease.
Who Should Not Take Mounjaro
Beyond the thyroid-related contraindications, Mounjaro is not approved for type 1 diabetes. It has not been studied in people with a history of pancreatitis, so its safety in that group is unknown. People with severe gastroparesis or other serious gastrointestinal conditions are advised against using it. And anyone with a known serious allergic reaction to tirzepatide or any of the drug’s ingredients should avoid it entirely.
For most people with type 2 diabetes or obesity who don’t fall into these categories, Mounjaro’s safety profile in clinical trials was manageable. The digestive side effects are real and sometimes unpleasant, but serious complications remained rare across thousands of study participants. The drug’s safety record continues to be monitored through postmarketing surveillance, and the FDA has actively updated the label as new information emerges.